Improved overall survival following tyrosine kinase inhibitor (TKI) treatment in NSCLC-are we making progress?

被引：2
|
作者：
Fenchel, Klaus [1 ,2 ]
Dale, Stephen P. [3 ]
Dempke, Wolfram C. M. [3 ,4 ]
机构：
[1] Med Sch Hamburg MSH, Hamburg, Germany
[2] Praxisklin Saalfeld Saale, Saalfeld, Germany
[3] Kyowa Kirin Pharmaceut Dev Ltd, Galashiels, Scotland
[4] Ludwig Maximilians Univ Munchen, Univ Hosp Grosshadern, Haematol & Oncol, Munich, Germany
来源：
TRANSLATIONAL LUNG CANCER RESEARCH | 2016年 / 5卷 / 04期
关键词：
RANDOMIZED CONTROLLED-TRIAL; MUTANT LUNG-CANCER; 1ST-LINE TREATMENT; PHASE-3; TRIAL; DOUBLE-BLIND; OPEN-LABEL; CHEMOTHERAPY; GEFITINIB; AFATINIB; ADENOCARCINOMA;
D O I：
10.21037/tlcr.2016.07.01
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：373 / 376
页数：4
相关论文
共 50 条
  • [21] the Charlson Comorbidity Index Predicts Survival Following Tyrosine Kinase Inhibitor Treatment in Chronic Myeloid Leukemia Patients
    Imataki, Osamu
    Uchida, Shumpei
    Oku, Maki
    Yokokura, Shigeyuki
    Uemura, Makiko
    Kadowaki, Norimitsu
    BLOOD, 2015, 126 (23)
  • [22] Fitness of RECIST 1.1 for non-small cell lung cancer (NSCLC) treated with EGFR tyrosine kinase inhibitor (TKI)
    Sun, Jong-Mu
    Park, Min Jae
    Yi, Jun Ho
    Kong, Jeehyun
    Kim, Jung-A
    Lee, Soohyeon
    Yun, Lin A.
    Lee, Jeeyun
    Park, Yeon Hee
    Ahn, Jin Seok
    Ahn, Myung-Ju
    Park, Keunchil
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S716 - S716
  • [23] Tailored tyrosine kinase inhibitor (TKI) treatment of chronic myeloid leukemia (CML) based on current evidence
    Ciftciler, R.
    Haznedaroglu, I. C.
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2021, 25 (24) : 7787 - 7798
  • [24] Economic burden of tyrosine kinase inhibitor (TKI) treatment failure in patients with chronic myeloid leukemia (CML).
    Chen, Yaozhu J.
    Huang, Hui
    Divino, Victoria
    Pokras, Shibani
    Hallinan, Shawn
    Munakata, Julie
    Taylor, Catherine
    McGarry, Lisa
    Ng, Daniel
    Nieset, Christopher
    Knopf, Kevin B.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [25] TKI258, a novel, multi-targeted tyrosine kinase inhibitor for the treatment of breast cancer
    Liu, Hongyu
    Dieing, Annette
    Lehenbauer-Dehm, Sylvia
    Kuehnhardt, Dagmar
    Regierer, Anne
    Schulz, Carsten
    Storek, Benjamin
    Schwarck, Sandra
    Possinger, Kurt
    Eucker, Jan
    CANCER RESEARCH, 2009, 69
  • [26] Allogeneic hematopoietic SCT in combination with tyrosine kinase inhibitor treatment compared with TKI treatment alone in CML blast crisis
    H Jiang
    L-P Xu
    D-H Liu
    K-Y Liu
    S-S Chen
    B Jiang
    Q Jiang
    H Chen
    Y-H Chen
    W Han
    X-H Zhang
    Y Wang
    J-Z Wang
    F-R Wang
    Y-Z Qin
    Y-Y Lai
    X-J Huang
    Bone Marrow Transplantation, 2014, 49 : 1146 - 1154
  • [27] Allogeneic hematopoietic SCT in combination with tyrosine kinase inhibitor treatment compared with TKI treatment alone in CML blast crisis
    Jiang, H.
    Xu, L-P
    Liu, D-H
    Liu, K-Y
    Chen, S-S
    Jiang, B.
    Jiang, Q.
    Chen, H.
    Chen, Y-H
    Han, W.
    Zhang, H.
    Wang, Y.
    Wang, J-Z
    Wang, F-R
    Qin, Y-Z
    Lai, Y-Y
    Huang, X-J
    BONE MARROW TRANSPLANTATION, 2014, 49 (09) : 1146 - 1154
  • [28] Overall survival (OS) in patients with EGFR-mutated new diagnosed stage IIIB/IV NSCLC in addiction of exon 19, 18/20 and 21 mutation and in addiction of treatment with tyrosine kinase inhibitor (TKI) or chemotherapy: A subgroup analysis of the REASON trial.
    Schuette, Wolfgang
    Behlendorf, Timo
    Schirmacher, Peter
    Eberhardt, Wilfried
    Dietel, Manfred
    Zirrgiebel, Ute
    Muehlenhoff, Lars
    Thomas, Michael
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [29] Macrocytosis as a potential parameter associated with survival after tyrosine kinase inhibitor treatment
    Kloth, Jacqueline S. L.
    Hamberg, Paul
    Mendelaar, Pauline A. J.
    Dulfer, Roderick R.
    van der Holt, Bronno
    Eechoute, Karel
    Wiemer, Erik A. C.
    Kruit, Wim H. J.
    Sleijfer, Stefan
    Mathijssen, Ron H. J.
    EUROPEAN JOURNAL OF CANCER, 2016, 56 : 101 - 106
  • [30] Patients with EGFR mutant (m) MET-altered NSCLC receiving tepotinib with an EGFR tyrosine kinase inhibitor (TKI): A case series
    Le, Xiuning
    Eisert, Anna
    Hsia, Te-Chun
    Raut, Nirmal Vivek
    Ahmad, Azura
    Chan, Oscar Siu Hong
    De Bondt, Charlotte
    Farrugia, David
    Froesch, Patrizia
    Gonzalez-Cao, Maria
    Hendriks, Lizza
    Hochmair, Maximilian J.
    Mazieres, Julien
    O'Sullivan, Hazel
    Samol, Jens
    van der Wekken, Anthonie J.
    Yang, Tsung-Ying
    Joshi, Kirti
    Vlassak, Soetkin
    Chang, Gee-Chen
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
12345